Edition:
United Kingdom

DBV Technologies SA (DBV.PA)

DBV.PA on Paris Stock Exchange

16.15EUR
16 Aug 2019
Change (% chg)

€0.27 (+1.70%)
Prev Close
€15.88
Open
€16.03
Day's High
€16.25
Day's Low
€15.90
Volume
81,293
Avg. Vol
213,837
52-wk High
€44.20
52-wk Low
€7.59

About

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to... (more)

Overall

Beta: 0.85
Market Cap(Mil.): €636.74
Shares Outstanding(Mil.): 36.16
Dividend: --
Yield (%): --

Financials

  DBV.PA Industry Sector
P/E (TTM): -- 29.73 33.85
EPS (TTM): -5.78 -- --
ROI: -122.98 13.04 12.69
ROE: -132.22 14.12 17.13

BRIEF-DBV Technologies: Potential Long-Term Benefit Of Viaskin Peanut

* ANNOUNCED ON SATURDAY THE COMPANY WILL PRESENT DATA FROM EPICUTANEOUS IMMUNOTHERAPY AT EAACI 2019

03 Jun 2019

BRIEF-DBV Technologies FY Net Loss Widens To 166.1 Million Euros

* REPORTED ON TUESDAY FY SALES AND MARKETING EXPENSES EUR 32.2 MLN VS EUR 15.8 MLN YR AGO

06 Mar 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates